For research and educational purposes only. Not medical advice.
Bacopa monnieri Reference
Educational, not medical advice reference for Bacopa monnieri: Nootropic, Cognitive; regulatory status, evidence posture, source review, and sch…
Reference summary
Bacopa has a long Ayurvedic tradition for 'medhya rasayana' (memory tonic) use. Modern human evidence is moderate for a botanical: multiple 8-12 week randomized trials in healthy adults and older adults (Stough 2001, Calabrese 2008, Morgan 2010, Roodenrys 2002) and a 2014 meta-analysis suggest small but reproducible improvements in delayed recall, learning rate, and information-processing speed, with effect sizes smaller than prescription cognitive enhancers. Pediatric ADHD-symptom trials are smaller and lower quality. Mechanistically, bacosides modulate cholinergic and serotonergic signaling, support BDNF expression, and act as antioxidants; rodent models also show dendritic-arborization changes that have not been demonstrated in humans.
Regulatory and posture
- Categories
- Nootropic, Cognitive
- Aliases
- Brahmi, Water hyssop, Bacognize, BacoMind, CDRI 08, KeenMind
- Evidence posture
- human - Sold as a dietary supplement, not as an FDA-approved drug. Effects on cognition are reported across multiple small trials; full effect requires 8-12 weeks of continuous use, and benefits are modest rather than dramatic. Not a treatment for dementia, ADHD, or any other diagnosed condition.
- Regulatory status
- No FDA-approved Bacopa drug label. Used for centuries in Ayurvedic medicine and sold in the US as a dietary supplement, typically standardized to 20-55 percent bacosides (Bacognize is a 12 percent standardization with a distinct extract profile; CDRI 08 / KeenMind is the most heavily studied standardization). Different extracts are not interchangeable on a per-milligram basis.
- Content review status
- research reference